Efficacy and Safety of Galantamine for Improving Dysfunction in People With Bipolar Disorder
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
This study will examine whether extended release galantamine, a drug approved by the Food and
Drug Administration to reduce cognitive impairments in people with Alzheimer's disease, can
perform the same function in stable people with bipolar disorder.
Phase:
Phase 4
Details
Lead Sponsor:
Icahn School of Medicine at Mount Sinai
Collaborators:
Massachusetts General Hospital National Institute of Mental Health (NIMH)